Home > Boards > US Listed > Medical - Drugs > Menlo Therapeutics Inc. (MNLO) (MNLO)

If one of the Phase III PN trials

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
PhenixBleu Member Profile
 
Followed By 67
Posts 7,048
Boards Moderated 5
Alias Born 05/06/14
160x600 placeholder
Robbins Geller Rudman & Dowd LLP Announce Proposed Settlement in the Menlo Therapeutics Inc. Securities Settlement Business Wire - 5/22/2020 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/11/2020 8:04:15 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/11/2020 7:09:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2020 5:55:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2020 5:55:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2020 5:55:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2020 5:54:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2020 5:54:15 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 5/7/2020 5:28:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 4:31:08 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/16/2020 12:47:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/10/2020 4:01:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:24:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:23:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:23:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:22:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:22:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:22:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2020 5:20:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/6/2020 9:00:58 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2020 4:48:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2020 4:42:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2020 4:42:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2020 4:33:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/25/2020 5:02:11 PM
PhenixBleu   Monday, 04/06/20 08:23:18 AM
Re: None
Post # of 305 
Quote:
If one of the Phase III PN trials fails to meet its primary endpoint at or before May 31, 2020, Foamix shareholders will receive an additional 0.6815 of a share of Menlo common stock for each Foamix share, increasing pro forma ownership of the combined company by Foamix shareholders to 76%

If both Phase III PN trials fail to meet their primary endpoints at or before May 31, 2020, Foamix shareholders will receive 1.2082 additional Menlo shares for each Foamix share, increasing pro forma ownership of the combined company by Foamix shareholders to 82%


https://www.globenewswire.com/news-release/2019/11/11/1944604/0/en/Foamix-and-Menlo-Therapeutics-to-Merge-Creating-a-Combined-Company-Focused-on-the-Development-and-Commercialization-of-Therapeutics-for-Dermatologic-Indications.html



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist